title: [Treating hypercholesterolemia - when and how].
abstract: Treating hypercholesterolemia reduces cardiovascular events in secondary and primary prevention. Familial hypercholesterolemia is a high risk constellation per se and LDL-cholesterol should be lowered early in life and significantly. Some novel agents will broaden our therapeutic options. The MTP-inhibitor Lomitapide, that reduces LDL-cholesterol independently of the LDL-receptor, and PCSK9-inhibitors, that reduce LDL-cholesterol by blocking the degradation of the LDL-receptor, were approved recently. Both novel therapeutic principles are promising. Further trials have to address long term safety and - as first data suggest in case of PCSK9-inhibitors - the reduction of cardiovascular events. One can expect that these novel agents will improve the risk adapted therapy - in combination with well-established therapies or in case of intolerances as mono-therapy.
authors.affiliation: Stoffwechselambulanz, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München.
authors.forename: Anja
authors.initials: A
authors.lastname: Vogt
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D006937:Hypercholesterolemia / Q000175:diagnosis* / Q000188:drug therapy*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; C473731:BMS201038; D001562:Benzimidazoles; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases